JPRN-UMIN000017033招募中2 期
A phase II neoadjuvant trial of sequential weekly nab-paclitaxel(nanoparticle albumin-bound paclitaxel) (abraxane) in HER2-negative patients, followed by 5-fluorouracil/ epirubicine/ cyclophosphamide (FEC) in operable breast cancer - neo-WABI BC
Tokyo Women's Medical University Department of Surgery II0 个研究点目标入组 42 人开始时间: 2015年4月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)History of drug-hypersensitivity. 2) Evaluated HER2(+) by IHC/FISH. 3) Active double cancer. 4)Synchronous bilateral breast cancer excluding contralateral non-invasive cancer (DCIS/LCIS) 5) Male patient. 6) Infection or suspected infection. 7) Abnormal ECG or serious cardiac disorder. (1)History of congestive cardiac failure.(NYHA class III/IV)) 8) Complication needed hospitalization. 9) Mental disease with difficulty of taking part in this study. 10) Administration of steroid. 11) HBV related marker (+). 12)Gastrointestinal bleeding. 13)Current pregnancy and lactation, or possibility of pregnancy. 14)Ineligible based on decision of an investigator.
研究者
相似试验
已完成
2 期
Randomized Phase II trial of Neoadjuvant weekly Nab-paclitaxel followed by FEC compared with Docetaxel followed by FEC for early breast cancerBreast CancerJPRN-UMIN000005388Department of Breast Surgical Oncology, Showa University150
进行中（未招募）
3 期
eo Adjuvant Chemotherapy in Triple Negative Breast CancerCTRI/2012/07/002802Tata Memorial Centre
进行中（未招募）
不适用
Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. - TVA studyRH- and Her2- operable breast cancer, in neoadjuvant situationMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2009-012853-39-FRCentre Jean Perrin
进行中（未招募）
1 期
Randomized Controlled Trial comparing two groups of Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity: the first one receiving Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab after surgery, and the second one receiving Radiotherapy and surgery, aiming to assess the safety and efficacy profile of PembrolizumabThis trial investigates whether neoadjuvant radiotherapy combined with pembrolizumab followed by surgical resection and adjuvant pembrolizumab improves disease-free survival for patients with high-risk soft tissue sarcoma of the extremity (undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, tumor size > 5 cm, grade 2 or 3 out of 3) compared to radiotherapy alone followed by surgical resectionMedDRA version: 20.0Level: PTClassification code 10024629Term: Liposarcoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10041298Term: Soft tissue sarcomas histology unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001360-39-ITSARC110
招募中
3 期
PRABITAS studycolorectal cancerJPRN-jRCTs041230120Taniguchi Hiroya890